Compare RBKB & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | TNYA |
|---|---|---|
| Founded | 1860 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.9M | 168.2M |
| IPO Year | 2018 | 2021 |
| Metric | RBKB | TNYA |
|---|---|---|
| Price | $12.48 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 203.3K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 215.00 | 54.96 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,984,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $62.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.41 | $0.53 |
| 52 Week High | $17.99 | $2.35 |
| Indicator | RBKB | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 31.68 | 49.84 |
| Support Level | $11.63 | $0.65 |
| Resistance Level | $12.63 | $0.80 |
| Average True Range (ATR) | 0.33 | 0.04 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 73.58 | 48.00 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.